First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study
2021 · The Breast · 6 citations
https://doi.org/10.1016/j.breast.2021.08.014